Sign in

Daniel Burton

Chief Executive Officer at Health Catalyst
Board
Since October 2012
Age
49 years
Education
Holds a Bachelor of Science degree from Brigham Young University and a Master of Business Administration from Harvard Business School.
Tenure
Joined HCAT as an adviser in January 2011, became a board member in September 2011, served as President from September 2011 to October 2012, and has been CEO since October 2012.

Also at Health Catalyst

BL
Benjamin Landry
General Counsel and Corporate Secretary
DL
Dan LeSueur
Chief Operating Officer
JA
Jason Alger
Chief Financial Officer (CFO)

About

Daniel Burton has built a diverse professional background with significant leadership roles in technology and healthcare industries. His career includes founding a private investment firm, leading corporate strategy initiatives at a major technology company, and working in consulting roles at renowned firms.

At HCAT, he began contributing as an adviser in January 2011 and quickly advanced to a board membership in September 2011, reflecting his valued expertise and leadership.

In October 2012, he assumed the role of Chief Executive Officer, overseeing strategic direction and growth at the company. His journey at HCAT, marked by a rapid ascent through key positions, underlines his effective management and extensive industry experience.

$HCAT Performance Under Daniel Burton

Past Roles

OrganizationRoleDate RangeDetails
Health Catalyst (HCAT) President September 2011 - October 2012 N/A
Health Catalyst (HCAT) Adviser January 2011 - September 2011 N/A
HB Ventures, LLC Co-founder/Adviser N/A Co-founded this private investment firm prior to joining HCAT
Micron Technology, Inc. Led Corporate Strategy Group N/A N/A
HP Inc. (HPQ) Strategy and Marketing Management N/A Spent eight years in strategy and marketing management roles
Boston Consulting Group Associate Consultant N/A Advised healthcare systems and technology companies

Fixed Compensation

Data from  FY 2023
Component NameAmountPayment ScheduleAdditional Details
Salary$0N/AVoluntarily reduced cash compensation by 100% from July 2022 through December 2023 due to cost reduction initiatives
Option Awards$0N/ANo stock options were granted during 2023
Stock Awards$0N/ADeclined equity grants including RSUs and PRSUs
Nonequity Incentive Plan Compensation$0N/ADeclined receiving the cash portion of the annual bonus for 2023
All Other Compensation$0N/ANo matching contributions under the 401(k) plan or other forms of compensation provided

Performance Compensation

Data from  FY 2023

No information available on performance compensation for 2023